Abstract
Background: Response to the COVID-19 pandemic calls for precision public health reflecting our improved understanding of who is the most vulnerable and their geographical location. We created three vulnerability indices to identify areas and people who require greater support while elucidating health inequities to inform emergency response in Kenya. Methods: Geospatial indicators were assembled to create three vulnerability indices; social (SVI), epidemiological (EVI) and a composite of the two (SEVI) resolved at 295 sub-counties in Kenya. SVI included nineteen indicators that affect the spread of disease; socio-economic inequities, access to services and population dynamics while EVI comprised five indicators describing comorbidities associated with COVID-19 severe disease progression. The indicators were scaled to a common measurement scale, spatially overlaid via arithmetic mean and equally weighted. The indices were classified into seven classes, 1-2 denoted low-vulnerability and 6-7 high-vulnerability. The population within vulnerabilities classes was quantified. Results: The spatial variation of each index was heterogeneous across Kenya. Forty-nine north-western and partly eastern sub-counties (6.9 m people) were highly vulnerable while 58 sub-counties (9.7 m people) in western and central Kenya were the least vulnerable for SVI. For EVI, 48 sub-counties (7.2 m people) in central and the adjacent areas and 81 sub-counties (13.2 m people) in northern Kenya were the most and least vulnerable respectively. Overall (SEVI), 46 sub-counties (7.0 m people) around central and south-eastern were more vulnerable while 81 sub-counties (14.4 m people) that were least vulnerable. Conclusion: The vulnerability indices created are tools relevant to the county, national government and stakeholders for prioritization and improved planning especially in highly vulnerable sub-counties where cases have not been confirmed. The heterogeneous nature of the vulnerability highlights the need to address social determinants of health disparities, strengthen the health system and establish programmes to cushion against the negative effects of the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
PMM is funded under the IDeAL Project, DELTAS Africa Initiative [DEL-15-003]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [number 107769/Z/10/Z] and the UK government. PMM is also supported by funds provided under Professor RW Snow Wellcome Trust Principal Fellowship (number 103602 and 212176). EAO is supported as Wellcome Trust Intermediate Fellow (number 201866) that provided support for NJK; NJK, PMM and EAO, acknowledge the support of the Wellcome Trust to the Kenya Major Overseas Programme (# 203077). The views expressed in this publication are those of the authors and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used secondary data only, all publicly available and can be accessed from different data repositories via references listed in Table 1. No individual patient level data used in this publication.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the datasets used in the current analysis are publicly available and can be accessed through references listed in Table 1 and in the supplementary files
